The primary aim of the DEDEMAS (Determinants of Dementia After Stroke) study is to identify predictors of post stroke dementia (PSD). A particular focus will be on biological markers (neuroimaging, biochemical markers derived from blood) and on interactions between vascular and neurodegenerative mechanisms. For this purpose patients with an acute stroke and without prior dementia will be followed for 10 years.
Note: Starting from 01.01.2014 this study is expanded to a multi-centric design funded by the German Center for Neurodegenerative Diseases (The DZNE - Mechanisms of Dementia After Stroke (DEMDAS) Study). This includes the following study sites: DZNE/München - Institute for Stroke and Dementia Research, Klinikum der Universität München (Coordinator); DZNE/Berlin - Neuroscience Research Center - Campus Mitte Charité; DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn; DZNE/Göttingen - University Medical Center Göttingen; DZNE/Magdeburg - Universitätsklinikum Magdeburg.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Language: German
* Acute stroke that occurred within the last 5 days as defined by:
acute focal neurological deficit in combination with one of the following:
* An acute ischemic infarct as documented by either a DWI positive lesion on MR imaging or a new lesion on a delayed CT scan
* An intracerebral hemorrhage as documented on CT or MRI
* An informant of the patient is available
* Written informed consent by patient prior to study participation
* Willingness to participate in follow-up
Exclusion Criteria:
* IQCODE \> 64 or diagnosis of dementia
* Patients transferred from an outside stroke unit (to avoid possible selection bias)
* Patients presenting a stroke going back more than 120 hours
* Patients presenting one of the following diseases: cerebral venous thrombosis, traumatic cerebral haemorrhage, intracerebral haemorrhage because of a known or image-guided assumed vascular malformation, pure meningeal or intraventricular haemorrhage
* Patients presenting a malignant disease with life expectancy \< 3years
* Contraindication for MRI
* Participation in an intervention/AMG-study at baseline
Primary outcome measure(s)
dementia occurrence — 5 years in DEMDAS this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family
dementia occurrence — 10 years in DEDEMAS this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family
Trial sites (5)
Facility
City
Region
Status
DZNE/Munich-Interdisciplinary Stroke Center Munich, Klinikum der Universität München, Campus Großhadern
Munich
Bavaria
DZNE/Berlin - Neuroscience Research Center - Campus Mitte Charité
Berlin
Germany
DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn
Bonn
Germany
DZNE/Göttingen - University Medical Center Göttingen
Göttingen
Germany
DZNE/Magdeburg - Universitätsklinikum Magdeburg
Magdeburg
Germany
More Ludwig-Maximilians - University of Munich trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.